Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.

@article{Filippatos2017PatientreportedOI,
  title={Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study.},
  author={Gerasimos S. Filippatos and Aldo Pietro Maggioni and Carolyn S. P. Lam and Elisabeth Pieske-Kraigher and Javed Butler and John A Spertus and Piotr P Ponikowski and Sanjiv J. Shah and Scott Solomon and Andrea-Viviana Scalise and Katharina Mueller and Lothar Roessig and Luke Bamber and Mihai Gheorghiade and Burkert Pieske},
  journal={European journal of heart failure},
  year={2017},
  volume={19 6},
  pages={782-791}
}
AIMS Exploratory assessment of the potential benefits of the novel soluble guanylate cyclase stimulator vericiguat on health status in patients with heart failure (HF) with preserved ejection fraction. METHODS AND RESULTS The SOCRATES-PRESERVED trial randomized patients with chronic HF and ejection fraction ≥ 45% within 4 weeks of decompensation to 12 weeks of treatment with titrated doses of vericiguat (1.25, 2.5, 5, and 10 mg once daily) or placebo. Health status was assessed with the… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS